Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lopinavir/Ritonavir and Arbidol in Novel Coronavirus Infection
NCT04252885Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2020
- Primary completion
- Apr 2020
- Countries
- 1
- Sponsor
- Guangzhou Eighth People's Hospital
- Modality
- Small Molecules
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 4, randomised, open-label trial of lopinavir + ritonavir and umifenovir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Guangzhou Eighth People's Hospital. Primary endpoint: Rate of virus inhibition at Day 21. Started Jan 2020; status: completed.
02
Design
3 arms- Study design
- RandomizedOpen-label
Group A-Standard treatment+lopinavir/ritonavir
Standard treatment + lopinavir (200mg) and ritonavir (50mg) (oral, q12h, 2 tablets each, 7-14 days)
Group B-Standard treatment+arbidol
Standard treatment + arbidol (100mg) (oral, tid, 200mg each time, 7-14 days)
Group C-Standard treatment
Standard treatment only
03
Who it enrols
Adults aged 18-80 with confirmed novel coronavirus infection, adequate renal and hepatic function, and no severe underlying diseases or interacting medications.
04
Endpoints
Primary
Rate of virus inhibition
Secondary
Disease prorogation-temperature
Disease prorogation-respiratory function 1
Disease prorogation-respiratory function 2
Disease prorogation-respiratory function 3
Beyond the preview
Go deeper on NCT04252885.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252885.